

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka
Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk
Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk
Web: http://www.epid.gov.lk

Vol. 42 No. 24

06th - 12th June 2015


Leishmaniasis

Leishmaniasis is a disease affecting predominantly people in the developing countries. 350 million people are at risk of contracting the disease and 2 million of new cases are reported yearly. The disease is caused by protozoan parasites from more than 20 Leishmania species.

Sri Lanka is endemic for cutaneous leishmaniasis by *Leishmania donovani*. First reported case of cutaneous leishmaniasis (CL) was in 1992.(Although a report describes several CL cases in 1978 which were imported from Saudi Arabia) Since then it has affected almost all provinces. During recent past the reason for its spread has been associated with the movement of military personnel into former uninhabited areas and over 2000 cases have been reported between 2001-2011,and this number is seen as an under-representation of the true incidence of the disease.

Infections are found in all ages, there is a difference, however between the North Central province, where most cases are in between the ages of 25 & 39 and mostly among the soldiers and in the south, where males and females are equally affected and most cases are between 10-19 years. The disease has been reported mostly in low altitude areas of Sri Lanka. However there are no data on seasonality are available in Sri Lanka.

Cutaneous leishmaniasis



Population movement, Overcrowding, poor access to health services, malnutrition ,lack of safe water, poor hygiene practices and poor sanitation (contributes to presence of sandfly) promotes the risk to contract the disease. Several recent cases of mucocutaneous leishmaniasis and visceral leishmaniasis (VL) were reported and the risk of future visceral leishmaniasis outbreaks is a concern and cannot be excluded.

Isolation of parasites in culture for the first time has been made in 2002 with 5 isolates confirming *Leishmania donovani*, which is the agent of cutaneous leishmaniasis in Sri Lanka and showed that these parasites are closely related to those causing visceral leishmaniasis in the Indian subcontinent.

Disease transmission & Clinical manifestations

Contents	Page
 Leading Article – Leishmaniasis Summary of selected notifiable diseases reported - (30th – 05th June 2015) Surveillance of vaccine preventable diseases & AFP - (30th – 05th June 2015) 	1 3 4

Human to human transmission occurs via a bite of haematophagous females of some sandfly species (*P.argentipes*) and through blood transfusions (rarely). The disease is not directly transmitted from person to person; however, the disease can infect sandflies as long as parasites remain in the lesions of untreated cases, which is usually from a few months to 2 years.

The incubation period varies from about 10 days to several months.

Human leishmaniasis may manifest as single or multiple skin lesions, often self-healing within a few months but leaving unsightly scars. Hosts develop acquired immunity through cellular and humoral responses, but infection can spread through the lymphatic and vascular system and produce more lesions in the skin (cutaneous, diffuse cutaneous leishmaniasis), the mucosa (mucocutaneous leishmaniasis) and invade the spleen, liver and bone marrow (visceral leishmaniasis). Common symptoms are fever, malaise, weight loss and anaemia, with swelling of the spleen, liver and lymph nodes in visceral human leishmaniasis.

Without treatment, most patients with the visceral disease will die and those with diffuse cutaneous and mucocutaneous disease can suffer long infections associated with secondary lifethreatening infections. Treatment should be considered even for self-healing cutaneous leishmaniasis, because of the disfiguring scars .

Diagnosis

CL-Clinical picture, confirmation with microscopic examination of skin lesion sample, PCR carried out in special laboratories.

VL-microscopic evaluation of splenic /bone marrow/lymph node aspirates.

Treatment

The treatment of leishmaniasis depends on several factors including type of disease, parasite species and geographic location. Leishmaniasis is a treatable and curable disease. All patients diagnosed as visceral leishmaniasis require prompt and complete treatment.

For cutaneous leishmaniasis cryotherapy is available in most district level hospitals. In some major hospitals with functional dermatology units, topical therapy with sodium stibogluconate is provided.

Prevention

WHO have designated leishmaniasis as a category 1 (emerging and uncontrolled) disease with prevention focused on vector control, control of animal reservoirs and research into potential vaccines. Prevention and control of leishmaniasis require a combination of intervention strategies because transmission occurs in a complex biological system involving the human host, parasite, sandfly vector and in some causes an animal reservoir host. Key strategies include:

- Early diagnosis and effective case management reduces
 the prevalence of the disease and prevents disabilities and
 death. Currently there are highly effective and safe antileishmanial medicines particularly for VL and access to these
 medicines has significantly improved.
- Vector control helps to reduce or interrupt transmission of disease by controlling sandflies, especially in domestic conditions. Control methods include insecticide spray, use of insecticide—treated nets, environmental management and personal protection.
- Effective disease surveillance is important. Early detection and treatment of cases helps reduce transmission and helps monitor the spread and burden of disease.
- Control of reservoir hosts is complex and should be tailored to the local situation.
- Social mobilization and strengthening partnerships –
 mobilization and education of the community with effective
 behavioural change interventions with locally tailored communication strategies. Partnership and collaboration with
 various stakeholders and other vector-borne disease control
 programmes is critical

Notification & Investigation

Leishmaniasis is a notifiable disease in Sri Lanka. Reporting of all suspected or confirmed cases of leishmaniasis to the Medical Officer of Health (MOH) is therefore a legal requirement. Once such a case is notified to the MOH, in addition to carrying out a routine investigation and reporting, a special investigation form should also be filled by the MOH staff and sent to the Epidemiology Unit through the Regional Epidemiologist. When a case is reported, the Regional Epidemiologist with the assistance from the Regional Malaria Officer/Office could carry out an entomological survey to identify the vector with a view to plan out effective control measures.

Sources

- 1.Siriwardana, H. V. Yamuna D. et al. 'Leishmania Donovani And Cutaneous Leishmaniasis, Sri Lanka'. Emerg. Infect. Dis. 13.3 (2007): 476-478. 08June 2015.
- 2. Athukorale DN, Seneviratne JK, Ihalamulla RL, Premaratne UN (1992). Locally acquired cutaneous leishmaniasis in Sri Lanka. J Trop Med Hyg 95(6):432-3.
- 3. Karunaweera ND (2009). Leishmania donovani causing cutaneous leishmaniasis in SriLanka: a wolf in sheep's clothing? Trends Parasitol 25(10):458-63.
- 4. Siriwardena HV, Udagedara CU, Karunaweera ND (2003). Clinical features, risk factors and
- efficacy of cryotherapy in cutaneous leishmaniasis in Sri Lanka. Ceylon Med J 48(1):10-2.
- 5. Rajapaksa US, Ihalamulla RL, Udagedera C, Karunaweera ND (2007). Cutaneousleishmaniasis in southern Sri Lanka. Trans R Soc Trop Med Hyg 101(8):799-803.
- 6. Rajapaksa US, Ihalamulla RL, Karunaweera ND (2005). First report of mucosal tissue localisation of leishmaniasis in Sri Lanka. Ceylon Med J 50(2):90-1.
- 7. Abeygunasekara PH, Costa YJ, Seneviratne N, Ratnatunga N, Wijesundera Mde S (2007).Locally acquired visceral leishmaniasis in Sri Lanka. Ceylon Med J 52(1):30-1.

Compiled by Dr.H.H.W.S.B Herath of Epidemiology Unit

30th - 05th June 2015 (23rd Week) Table 1: Selected notifiable diseases reported by Medical Officers of Health

lable	1.	OCIC	, C (C	u III	Otill	avic	, uis	eas) C 3	ep	oi le	u D	y IVI	uic	aı	JIII	cers	ot	пеа	ILII	31	յ տ -	ี 05"	· Jt	IIIE	201	J (Z	.J	VV
WRCD	ئ	31	0	œ	•	31	23	25	25	0	17	20	70	20	40	14	29	22	15	31	26	22	29	0	22	18	23	70	
W	<u>*</u>	69	100	95	100	69	77	75	75	100	83	20	80	20	9	86	71	75	85	69	74	43	71	100	78	82	77	80	
Leishmani- asis	Ф	0	2	0	7	е	0	2	143	42	0	0	0	7	4	0	∺	П	53	2	146	49	9	13	4	0	0	480	
Leish asis	⋖	0	0	0	4	0	0	1	9	7	0	0	0	0	0	0	н	0	က	0	9	П	0	н	0	0	0	22	
gitis	В	22	10	27	∞	4	29	26	2	11	œ	0	0	9	٣	15	5	m	20	15	17	13	45	7	22	29	7	360	
Meningitis	⋖	0	0	7	0	0	0	0	0	0	0	0	0	П	0	٣	щ	0	7	0	П	0	က	0	7	0	0	15	
xodue	Ф	244	113	153	124	13	61	134	72	133	135	11	7	33	2	23	123	45	231	29	107	74	106	48	63	123	99	2273	
Chickenpox	∢	7	4	П	9	0	7	9	0	П	2	0	0	н	0	0	m	7	4	0	0	က	Ŋ	т	н	4	0	28	
nan ies	В	٣	0	1	0	0	0	0	0	0	2	П	0	7	0	0	0	П	က	0		0	7	П	0	0	0	17	
Human Rabies	∢	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	Ħ	
Viral Hepatitis	Ф	17	80	15	84	20	40	4	24	16	6	0	0	П	7	0	2	7	28	1	8	က	6	39	131	27	0	685	
	⋖	0	2	0	7	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	0	0	4	0	7	0	0	15	
Typhus Fever	В	9	9	1	32	7	35	31	27	19	502	12	16	12	7	7	П	11	17	10	16	П	09	44	36	29	0	943	
Typhu	⋖	0	0	1	Н	1	0	0	0	0	æ	0	0	0	0	0	Н	0	П	0	П	0	4	0	П	0	0	14	
Leptospirosi s	В	136	229	157	54	33	15	123	20	93	13	1	œ	12	3	8	10	11	141	24	161	45	34	121	153	171	3	1809	
Lept	∢	3	11	7	က	С	Н	1	1	7	П	0	0	0	0	0	0	0	9	1	9	က	0	П	2	7	0	62	
Food Poisoning	ω	29	25	29	25	4	0	14	10	4	41	27	2	4	1	123	4	32	13	9	49	က	7	2	н	2	30	909	
Poi	∢	0	П	н	0	0	0	0	H	0	0	0	0	0	0	0	0	н	0	0	0	0	0	0	0	0	0	4	
Enteric Fever	Ф	44	18	22	17	9	6	4	2	4	140	2	2	41	2	12	н	17	က	3	2	7	4	13	22	45	н	458	
	∢	0	0	0	Н	0	0	0	0	0	7	0	0	7	0	0	0	0	0	0	0	0	0	↔	0	н	0	7	
Encephalit is	ω	2	С	4	72	0	m	П	0	2	∞	0	↔	9	7	4	↔	0	7	4		7	4	7	2	7	П	26	
	⋖	0	0	0	0	0		0	0	0	0	0	0	0	0		0	0	0	0	0	0	П	0	0	0	0	1	<u>(</u>
Dysentery	a	93	49	54	62	29	184	32	14	38	299	41	9	10	11	134	25	24	82	23	43	26	78	09	143	37	67	1664	ases (WRC
۵	⋖	11	2	7	n	0	6	0	0	1	11	0	0	0	0	3	0	П	н	2	n	0	7	က	2	1	3	. 56	le Dise
Dengue Fever	Ф	4327	2076	737	929	311	88	383	156	225	1070	34	74	77	82	1176	27	437	763	430	261	126	341	107	515	296	393	15171	ommunicab
Denc	∢	69	55	17	18	1	0	1	1	4	11	0	п	m	2	23	П	∞	13	2	4	1	က	က	11	2	0	260	urns of Co
RDHS Division		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmunei	SRILANKA	Source: Weekly Returns of Communicable Diseases (WRCD)

f Communicable Diseases (WRCD).
•T=Timeliness refers to returns received on or before 05⊪June , 2015 Total number of reporting units 337 Number of reporting units data provided for the current week: 273 C**-Completeness

Table 2: Vaccine-Preventable Diseases & AFP

30th - 05th June 2015 (23rd Week)

Disease			N	lo. of Cas	es by P	rovince			Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date		
	W	С	S	N	Е	NW	NC	U	Sab	week in 2015	week in 2014	2015	2014	in 2014& 2015	
AFP*	01	00	00	00	00	00	00	00	00	01	01	30	42	-28.5%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	%	
Mumps	00	02	00	00	03	02	00	01	02	10	06	183	329	-44.3%	
Measles	23	06	06	03	01	03	02	04	04	52	30	1112	1855	-0.4%	
Rubella	00	00	00	01	00	00	00	00	00	01	01	06	13	-54.1%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	03	-100%	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	07	08	-12.5%	
Neonatal Teta- nus	00	00	00	00	00	00	00	00	00	00	00	00	00	%	
Japanese En- cephalitis	00	00	00	00	00	00	00	00	00	00	01	07	18	-61.1%	
Whooping Cough	01	00	00	00	00	01	00	00	01	3	00	37	26	+42.3%	
Tuberculosis	73	02	03	00	09	01	00	09	03	100	265	4156	4437	-6.3%	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

AFP and all clinically confirmed Vaccine Preventable Diseases except Tuberculosis and Mumps should be investigated by the MOH

Dengue Prevention and Control Health Messages

Look for plants such as bamboo, bohemia, rampe and banana in your surroundings and maintain them

PRINTING OF THIS PUBLICATION IS FUNDED BY THE WORLD HEALTH ORGANIZATION (WHO).

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE